GlassScriptPhysician profile
Evan Ryan Restelli
NPI 1003923814
$10,002.34
in general payments reported to CMS, 2019-2025
28 companies · $2,933 in 2025
The $2,933 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $131 · 2021: $899 · 2022: $1,729 · 2023: $1,646 · 2024: $2,207 · 2025: $2,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,528 · Travel and Lodging: $190 · Education: $68.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,527.84 |
| Travel and Lodging | $190.20 |
| Education | $68.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,921.93 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $2,211.00 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $688.34 | 2019-2025 | |
| Amgen INC. | $653.63 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $469.63 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $462.92 | 2021-2025 | Prolastin-C Liquid |
| Insmed, INC. | $449.50 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.11 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| United Therapeutics Corporation | $331.97 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Inspire Medical Systems, INC. | $259.79 | 2024 | Inspire |
| Baxter Healthcare | $220.76 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $145.14 | 2019-2023 | Esbriet, Xolair |
| Merck Sharp & Dohme LLC | $138.31 | 2023-2025 | Zerbaxa, Keytruda, Capvaxive |
| Emd Serono, INC. | $97.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $96.21 | 2025 | Purified Cortrophin Gel |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $83.06 | 2023 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $79.58 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $53.32 | 2023 | Acthar |
| Edwards Lifesciences Corporation | $37.84 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Jazz Pharmaceuticals INC. | $35.90 | 2019-2020 | |
| Advanced Respiratory, INC | $27.16 | 2021 | |
| Electromed, INC. | $25.59 | 2024 | Smartvest |
| Pfizer INC. | $23.95 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.14 | 2023 | Ultomiris |
| Mylan Specialty L.P. | $18.91 | 2019 | |
| Medtronic, INC. | $18.02 | 2023 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $15.31 | 2022 | |
| Philips North America LLC | $14.36 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Restelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.